References
  1. Roden DM (2004) Drug-Induced Prolongation of the QT Interval. N Engl J Med350: 1013-1022.
  2. Passman R, Kadish A (2001) Polymorphic ventricular tachycardia. Long QT syndrome, and torsades de pointes. Med Clin North Am 8: 32.
  3. Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89: 1363.
  4. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy, 2001; 21: 1468–1472.
  5. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther, 2003; 73: 292–303.
  6. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol, 2006; 11: 52–56.
  7. Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: Is this a significant “clinical” event? South Med J, 2006; 99: 52–56.
  8. Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001;296:806–10.
  9. Liu X, Ma J, Haung J, et al. Fluoroquinolones increase the risk of serious arrhythmias. A systematic review and meta-analysis. Medicine, 96:44.
  10. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents, 2007; 29:374–379.
  11. Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm. 2004;1(5):624-626. doi:10.1016/j.hrthm.2004.06.020.
  12. Keivanidou A, Arnaoutoglou C, Krommydas A, et al. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J. 2009;16(2):172-174.
  13. Flanagan MC, Mitchell ES, Haigney MC. Ciprofloxacin-induced torsade de pointes. Int J Cardiol. 2006; 113(2):239-241. doi:10.1016/j.ijcard.2005.08.048.
  14. Nair MK, Patel K, Starer PJ. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient. Addiction. 2008;103(12):2062-2064. doi:10.1111/j.1360-0443.2008.02390.x
  15. Ibrahim M, Omar B. Ciprofloxacin-induced torsade de pointes. Am J Emerg Med. 2012; 30(1):252.e5-252.e2.52E9. doi:10.1016/j.ajem.2010.09.039
  16. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010; 55(9):934-947. doi:10.1016/j.jacc.2010.01.001
  17. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Heart Rhythm. 2018 Sep 26;:]. Heart Rhythm. 2018; 15(10):e190-e252. doi:10.1016/j.hrthm.2017.10.03.